Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of ANI Pharmaceuticals Inc (NASDAQ: ANIP) closed at $91.14 in the last session, up 0.57% from day before closing price of $90.62. In other words, the price has increased by $0.57 from its previous closing price. On the day, 0.64 million shares were traded. ANIP stock price reached its highest trading level at $91.49 during the session, while it also had its lowest trading level at $89.2896.
Ratios:
We take a closer look at ANIP’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.77. For the most recent quarter (mrq), Quick Ratio is recorded 1.96 and its Current Ratio is at 2.54. In the meantime, Its Debt-to-Equity ratio is 1.48 whereas as Long-Term Debt/Eq ratio is at 1.45.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 10, 2025, initiated with a Buy rating and assigned the stock a target price of $84.
On March 14, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $80.
On March 12, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $85.JP Morgan initiated its Overweight rating on March 12, 2025, with a $85 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 21 ’25 when Shanmugam Muthusamy bought 52,988 shares for $90.44 per share.
Shanmugam Muthusamy bought 47,012 shares of ANIP for $4,243,703 on Aug 20 ’25. On Aug 18 ’25, another insider, Thoma Jeanne, who serves as the Director of the company, sold 21,540 shares for $89.15 each. As a result, the insider received 1,920,370 and left with 23,405 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANIP now has a Market Capitalization of 1976717184 and an Enterprise Value of 2250581248. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.65 while its Price-to-Book (P/B) ratio in mrq is 4.53. Its current Enterprise Value per Revenue stands at 3.011 whereas that against EBITDA is 21.573.
Stock Price History:
The Beta on a monthly basis for ANIP is 0.60, which has changed by 0.47762644 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, ANIP has reached a high of $91.15, while it has fallen to a 52-week low of $52.50. The 50-Day Moving Average of the stock is 30.27%, while the 200-Day Moving Average is calculated to be 44.52%.
Shares Statistics:
According to the various share statistics, ANIP traded on average about 430.20K shares per day over the past 3-months and 1058400 shares per day over the past 10 days. A total of 21.72M shares are outstanding, with a floating share count of 18.14M. Insiders hold about 16.40% of the company’s shares, while institutions hold 91.93% stake in the company. Shares short for ANIP as of 1753920000 were 2209541 with a Short Ratio of 5.14, compared to 1751241600 on 2005000. Therefore, it implies a Short% of Shares Outstanding of 2209541 and a Short% of Float of 12.78.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of ANI Pharmaceuticals Inc (ANIP) is underway, with the input of 7.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $2.02, with high estimates of $2.17 and low estimates of $1.86.
Analysts are recommending an EPS of between $7.36 and $7.07 for the fiscal current year, implying an average EPS of $7.23. EPS for the following year is $7.68, with 8.0 analysts recommending between $8.8 and $6.26.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $207.66M. It ranges from a high estimate of $215.34M to a low estimate of $204M. As of the current estimate, ANI Pharmaceuticals Inc’s year-ago sales were $148.33MFor the next quarter, 7 analysts are estimating revenue of $222.89M. There is a high estimate of $230.03M for the next quarter, whereas the lowest estimate is $217.1M.
A total of 7 analysts have provided revenue estimates for ANIP’s current fiscal year. The highest revenue estimate was $853.87M, while the lowest revenue estimate was $829.8M, resulting in an average revenue estimate of $839.14M. In the same quarter a year ago, actual revenue was $614.38MBased on 8 analysts’ estimates, the company’s revenue will be $909.18M in the next fiscal year. The high estimate is $990.3M and the low estimate is $834.01M.
